Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103103 · ClinicalTrials.gov registry record · Phase 2
Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer
A Phase 2 study, sponsored by California Cancer Consortium.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00103103 is a Phase 2 study that was terminated before completion, run by California Cancer Consortium.
The verdict
NCT00103103, a Phase 2 study, was terminated before completion, sponsored by California Cancer Consortium.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with fluorouracil and leucovorin may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving bortezomib together with fluorouracil and leucovorin works in treating patients with metastatic or unresectable stomach cancer.
Interventions
- DRUG fluorouracil
- DRUG leucovorin calcium
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-03 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00103103
The ClinicalTrials.gov registry entry for NCT00103103 describes a study currently listed as terminated, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is California Cancer Consortium, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which fluorouracil is the first listed.
NCT00103103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00103103 about?
NCT00103103 is a clinical study titled "Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer". RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. G...
What is the current status of trial NCT00103103?
This trial is currently terminated. It is a Phase 2 study. The study started on 2005-03. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00103103?
The interventions under investigation include: fluorouracil (DRUG), leucovorin calcium (DRUG), bortezomib (DRUG).
Who is sponsoring clinical trial NCT00103103?
This trial is sponsored by California Cancer Consortium, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.